Several critical developments underscored
Sanofi's performance in the biotech sector. Predominantly, the company embarked on a licensing deal with
Novavax worth $1.2bn, causing a surge in Novavax's stock.
Sanofi and Novavax will co-commercialize a Covid-19 vaccine and develop combined shots. But, a 'full pipeline' shakeup led to
job cuts and research halting. Additionally, a Hawaii court ordered
Sanofi and Bristol Myers Squibb to pay $916m due to a Plavix marketing case. On a positive note,
Sanofi struck deals with
OpenAI and
Formation Bio to boost AI-powered drug development and discovery. Moreover,
Sanofi exhibited promising results from a phase II asthma treatment trial, demonstrating an innovative oral treatment. A restructuring of the US commercial vaccine group and job cuts in the vaccine division represent proactive steps
Sanofi is performing for optimization.
Sanofi News Analytics from Fri, 01 Sep 2023 23:17:18 GMT to Sun, 26 May 2024 12:05:24 GMT -
Rating 2
- Innovation 6
- Information 5
- Rumor -4
